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Patient global assessment in measuring
disease activity in rheumatoid arthritis: a
review of the literature
Elena Nikiphorou1* , Helga Radner2, Katerina Chatzidionysiou3,4, Carole Desthieux5,6, Codruta Zabalan7,
Yvonne van Eijk-Hustings8,9, William G. Dixon10, Kimme L. Hyrich11, Johan Askling3,4 and Laure Gossec5,6
Abstract
Patient-reported outcomes (PROs) reflect the patient’s perspective and are used in rheumatoid arthritis (RA) routine
clinical practice. Patient global assessment (PGA) is one of the most widely used PROs in RA practice and research and
is included in several composite scores such as the 28-joint Disease Activity Score (DAS28). PGA is often assessed by a
single question with a 0–10 or 0–100 response. The content can vary and relates either to global health (e.g., how is
your health overall) or to disease activity (e.g., how active is your arthritis). The wordings used as anchors, i.e., for the
score of 0, 10, or 100 according to the scale used, and the timing (i.e., this day or this week) also vary. The different
possible ways of measuring PGA translate into variations in its interpretation and reporting and may impact on
measures of disease activity and consequently achievement of treat-to-target goals. Furthermore, although PGA is
associated with objective measures of disease activity, it is also associated with other aspects of health, such as
psychological distress or comorbidities, which leads to situations of discordance between objective RA assessments
and PGA. Focusing on the role of PGA, its use and interpretation in RA, this review explores its validity and correlations
with other disease measures and its overall value for research and routine clinical practice.
Keywords: Rheumatoid arthritis, Patient global assessment, Discordance
Background
Patient-reported outcomes (PROs) are increasingly recog-
nized for their value in providing the patient’s perspective on
aspects of their condition or their overall health status. Their
incorporation into clinical practice and in research in
rheumatoid arthritis (RA) is widely supported by international
organizations and professional bodies [1, 2], including the
European Patients’ Academy on Therapeutic Innovations
(EUPATI; http://www.patientsacademy.eu/index.php/en/) and
the Patient-Centered Outcomes Research Institute (PCORI;
http://www.pcori.org/research-results) in the United States, as
well as regulatory agencies such as the Food and Drug
Administration (http://www.fda.gov/) and the European
Medicines Agency (http://www.ema.europa.eu/ema/), all of
whom recognize the patient’s unique position in providing
direct feedback on their disease.
Patient global assessment (PGA) is one of the most
widely reported PROs in RA. The considerable burden of
RA on the individual is related to both inflammation and
damage but also to broader aspects of disease, including
psychological and societal impact. The use of PROs like the
widely used Health Assessment Questionnaire (HAQ) or
the PGA allows a more holistic assessment of disease be-
yond objective measures of inflammation or structural
damage, such as acute phase reactants or radiographic
damage. Experts from the American College of Rheumatol-
ogy (ACR), the European League Against Rheumatism
(EULAR), and the Outcome Measures in Rheumatology
Clinical Trials (OMERACT) have endorsed a “core set” of
data for use in RA clinical trials which includes PGA [3, 4].
In recent randomized controlled trials and observational
studies in RA, PGA has been reported in 49 % of studies,
making it the second most frequently collected PRO after
physical function (68 %) [5]. PGA is also incorporated into
several of the major outcome and disease activity scores in
RA, often as the only PRO: these include the ACR/EULAR
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remission criteria, the 28-joint count Disease Activity Score
(DAS28), the Simplified Disease Activity Index (SDAI), the
Clinical Disease Activity Index (CDAI), and the Routine
Assessment of Patient Index Data (RAPID3).
However, the use of PGA in RA presents many chal-
lenges and limitations. The several possible ways of meas-
uring PGA, including the intended assessment or
underlying concept (i.e., global health versus disease activ-
ity) and variations in wording/phrasing and time period
assessed may lead to differences in interpretation of PGA.
Discordance with objective RA measures is also an issue
that needs to be addressed. The latter is particularly im-
portant in the context of treating to target aiming for re-
mission and shared decision-making [6, 7]. What the
different formulations of PGA are, their impact, and justi-
fications for their use remain to be clarified.
To provide readers with a complete overview regard-
ing PGA in RA, a review of the literature was under-
taken based on a hierarchical literature search including
hand searches and expert opinion searches covering key
publications in the field. The objectives were to explore
the value of PGA as an outcome measure in RA, focus-
ing on its psychometric properties (feasibility, validity,
reliability, and sensitivity to change). Specifically, this re-
view discusses the validity and impact of different word-
ings/phrasings and time period assessed as part of PGA
on patients’ assessment of disease, as well as discordance
between physician global assessment and PGA.
Description and practical application
Concepts behind PGA
PGA was developed in the late 1970s and was initially de-
signed for the measurement of self-assessed pain in RA
[8], although it has since been used to evaluate RA more
globally. It is interesting to note that the way PGA is used
in clinical practice covers, in fact, two very different con-
cepts, one related to global health and the other to overall
disease activity. They are both usually used under the
heading of PGA without further specification for which is
being assessed.
PGA wording and phrasing
It is well-recognized that the wording/specific phrasing
used for PROs may result in a varied response [9–12]. In
the case of PGA, its exact wording/phrasing was not spe-
cified when developed; however, it was suggested that it
could be used for two main purposes—either a patient as-
sessment of global health or of disease activity—stemming
from the two basic concepts (Table 1) [11, 13]. Over the
past years many different wordings/phrasings of PGA have
been formulated, covering variations of these two con-
cepts [14–18]. Furthermore, anchor wordings may also
vary, e.g., words used to describe the right end of the score
(corresponding to scores of 10 or 100) from “worst pos-
sible” to “most active” to “very active”, for example.
Although the wording/phrasing of PGA remains un-
standardized to date, the ACR/EULAR remission criteria
do specifically propose the following phrasing related to
disease activity: “Considering all the ways your arthritis
has affected you, how do you feel your arthritis is
today?” [19].
PGA reference period
Aside from different wording/phrasing used for the
question stem, the reference periods to describe the time
component (i.e., the period of recall the patient should
refer to when answering the question) can also vary
(Table 1). As we will see in this review, the different for-
mulations of PGA lead to differences in interpretation.
In the context of a EULAR taskforce to standardize data
collection across registries, in 2015 we contacted registries
and cohorts across Europe to explore outcomes being
assessed: 52 out of 67 (78 %) registries were collecting
some form of PGA [20]. The versions of the PGA used
varied with regard to the concept, wording/phrasing, and
reference period used. More recently, a smaller pilot sur-
vey in 2016 (unpublished data) indicated that 6/16 (38 %)
cohorts were assessing disease activity-PGA (either related
to RA or not specifically related to RA) whereas 6/16
(38 %) were assessing global health PGA and 4/16 (25 %)
were assessing both concepts. Some wordings as trans-
lated by the investigators are shown in Table 1. With re-
gard to the reference period, 41 % reported “today” as
being the time reference used, with the second most com-
mon being “last week” (35 %).
PGA scoring
Depending on the type of score used, the PGA can range
from 0–100 mm, although is often reported from 0–
10 cm. Higher scores represent a higher level of disease
activity or a worse global health. The proposed definition
of “low global assessment” is ≤2.0 (scale 0–10) [21].
PGA may be scored using a numeric rating scale (NRS),
a verbally administered NRS, or a visual analogue scale
(VAS). The PGA-VAS is classically anchored on an unnum-
bered 10-cm/100-mm horizontal line but may also be ad-
ministered as a vertical VAS. The VAS may be anchored at
the ends (e.g., with defined adjectives at the ends such as
best versus worst) or open. Sometimes the PGA is pre-
sented with tick marks at periodic intervals or as a VAS
consisting of 21 circles at 0.5-mm intervals, the latter
shown to be similar to a classic 10/100 scale [22]. In prac-
tice, sometimes these exact definitions are not followed
(e.g., the line is not 10 cm long or there are not 21 circles
evenly spaced) and these technical difficulties may hamper
the use of PGA (as is the case with other PROs). A Likert-
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style scale may also be used, though its metric properties
are different.
A study comparing responses to a global health VAS
presented both as a 10/100 cm horizontal scale with no
incremental markers and as a vertical 20/100 cm VAS
with 1-cm markers concluded that different presentation
of scales, order effect, and incremental markers can affect
scoring [14]. Another study comparing different scaling of
PGA revealed similar construct validity for VAS and NRS
but higher sensitivity to change of VAS [23]. Although
some differences can be seen in scoring methods for PGA,
all methods appear at this point similarly valid. We would,
however, recommend the use of either an unnumbered
horizontal VAS or a numbered horizontal NRS since these
formats are the most usual and most used.
Psychometric properties of PGA
The main strengths and weaknesses of PGA are summa-
rized in Table 2. Below, we review each psychometric
property of PGA.
Feasibility
Like other PROs, including, for example, the HAQ, PGA
is a very feasible measure. PGA is administered as a sim-
ple, single-item (with no subscale), patient-completed
question measuring the overall way RA affects the pa-
tient and/or disease activity at a specific point in time.
There is no cost attached to it, it is practical, and can be
self-administered. The single question takes only a few
seconds to ask, making it feasible in routine clinical set-
tings but also as an end-point in clinical trials in RA and
is one of the main strengths of the PGA, making it one
of the most frequently reported domains across pub-
lished RA studies [6].
Face validity
PGA is a global, “gestalt” measure of disease which ap-
pears to encompass many aspects of disease which are im-
portant for patients. Physicians’ assessment of RA disease
activity is mainly driven by objective criteria, i.e., tender/
swollen joint counts and level of inflammation, whereas it
seems patients place more focus on overall well-being,
levels of pain, and health-related quality of life [24]. The
latter, in particular, seems to have the greatest relevance
and meaning to patients. However, it is often difficult to
capture health-related quality of life with simple question-
naires. In this sense, PGA appears of interest since it may
summarize in one simple measure many aspects of disease
and health which are important to patients.
Although PGA has high face validity (Table 2), it does
present some challenges. A major point is the patient’s in-
terpretation of the PGA, both depending on the concept
(i.e., global health versus disease activity) and on the pa-
tient’s individual comprehension of this broad question.
For both concepts behind PGA, a criticism is that the re-
sponse to the question may both reflect a broad under-
standing of the patient’s health and also be influenced by a
number of factors, making it difficult to discern what as-
pect of disease contributes to the overall score. Structural
damage (related to disease duration) and other aspects of
patients’ lives (such as comorbidities or psychological dis-
tress) may have an impact on the scoring of PGA [1].
In both cases of PGA (i.e., global health versus disease
activity), interpretation of the question by the patient may
depend on duration of disease through a “response shift”
(i.e., a change in the meaning of a patient’s self-evaluation)
resulting from a better knowledge of symptoms and
changes in patient expectations [25]. In the current bio-
logic era, however, cumulative damage is considerably
Table 1 Different concepts covered by PGA and examples of different types of wording used
Concept Attribution
to RA
Example question Reference period
Disease
activity
Related to
arthritis
“Considering all the ways your arthritis has affected you, how active do you feel your arthritis is
…”
“Considering the tenderness, pain, and swelling of joints, how active is your rheumatoid arthritis
....”
“In general, how active has your rheumatic condition been?”
“How active do you consider your arthritis?”
“In terms of joint tenderness (i.e., joint pain associated with light touch) and joint swelling (i.e.,
joint enlargement due to inflammation), how active would you say your rheumatic condition is
today?’
Today
Over the past 2 days
Last week
Last month
Unspecified time period
Overall “How do you estimate your disease activity ..?”
Global
health
Related to
arthritis
“Considering all the ways your arthritis has affected you, how would you say your health is …”
“Considering all the ways in which your illness affects you at this time, please make a mark
below to show how you are doing”
“How has your arthritis affected you today?”
“Considering all the ways your arthritis affects you, rate how well you are doing on the
following scale…”
Overall “Considering all the ways in which illness and health conditions may affect you at this time,
please make a mark below to show how you are doing”
“In general how would you say your health is”
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lower despite longer disease duration and therefore the ef-
fect and meaning of a response shift may have a different
interpretation. Differences in patients’ perceptions regard-
ing internal standards, values, or conceptualization of
health-related quality of life can result in “ambiguous” or
“paradoxical” findings [25]. For example, patients with
long-standing disability may report a good or high quality
of life (despite what externally might appear paradoxically
untrue) due to several factors, such as acceptance and the
opportunity to adjust and achieve stability through several
transition phases while living with disability. All these fac-
tors need to be taken into account when interpreting indi-
viduals’ PGA scores.
Reliability
Data on the reliability of PGA, which refers to the repro-
ducibility in a test–retest setting, are reassuring [26–28].
Studies have shown the PGA intraclass correlation coef-
ficient (as a measure of test–retest reliability) to be gen-
erally acceptable to high, though lower than ones noted
for physician global assessment [29, 30]. The data avail-
able in the literature do not allow us to directly compare
reliability of PGA–global health versus PGA–disease ac-
tivity; although when tested separately, both appear to
have acceptable reliability.
Sensitivity to change
Sensitivity to change indicates that the measure will im-
prove when the underlying conceptual framework (here,
either global health or disease activity) improves. PGA
has been shown to be sensitive to change, which makes
it a very useful clinical measure in assessing RA, particu-
larly in clinical trials. PGA detects improvement after ac-
tive treatment better than, for example, tender joint
count [31]. Table 3 summarizes key findings in this area.
Furthermore, PGA has been shown to discriminate
active treatment from placebo in randomized controlled
trials, with treatment-associated changes being congru-
ent with measures of inflammation, suggesting close re-
flection of other criteria related to the RA process, such
as joint counts [32].
In support of the above, in an analysis of the efficien-
cies to distinguish active treatment from control treat-
ments in clinical trials, among the seven RA core set
measures, the highest relative efficiencies were for the
physician global estimate followed by PGA and physical
function [33]. “Objective” measures of disease, such as
acute phase reactants and tender and swollen joint
counts, were not superior to “subjective” global esti-
mates of the physician or patient self-report measures of
physical function or pain to differentiate active from
control treatments. These findings challenge the view
that laboratory and clinical examination findings are
more robust than patient self-report measures in asses-
sing and monitoring disease progression and treatment
response in RA [33].
Consequences of different wordings/phrasings
The heterogeneity in the wording/phrasing of PGA re-
quires caution when interpreting the results [34]. The
DAS28 is one of the most commonly used composite
scores in routine clinical practice; the PGA component
of the score carries a small weighting of 0.014, which
may still result in differences to the overall DAS28 score
(the maximum difference being 1.4 when holding the
other variables constant and using first a PGA-VAS
score of 0 mm, then of 100 mm). French et al. [11]
performed a study where DAS28 was calculated in the
same patients when using different PGAs. Five different
versions of the PGA-VAS were assessed based on: (1)
“Feeling” (“How do you feel concerning your arthritis
over the last week?”); (2) Disease activity (“How active
Table 2 Major strengths and weaknesses of PGA in RA
Strengths Weaknesses
Practical and feasible to collect: much more easily
collected than joint counts, acute phase reactants,
or radiographic damage
(simple, single-item tool)
Heterogeneity in concept (i.e., global health versus disease activity) and attribution to RA
or other co-existing health conditions and wording/phrasing, all leading to possible het-
erogeneity in the responses
No cost, non-invasive and self-administered Heterogeneous phrasing of the time-frame (today, last week, etc.) applied to PGA
May summarize all aspects of disease important
to the patient
(face validity)
Very broad concept leading to interpretation difficulties
Practical and feasible to interpret: easy to score,
incorporate in composite scores, and analyze
Difficulties of interpretation due to uncertainty regarding attribution to permanent
damage related to RA compared to inflammation and disease activity
Good test–retest reliability Difficulties of interpretation due to uncertainty regarding attribution to RA versus non-RA
disease, including psychological distress and comorbidities
Good sensitivity to change in clinical trials May be influenced by patient education level
Discordance between PGA and physician assessment:
brings in additional information
Discordance between PGA and physician assessment: what impact on decision making?
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has your disease been this week?”); (3) “Well-being”
(“How has your overall well-being been this week?”); (4)
“Best/worst” (“If 0 is the best you have ever been and
100 is the worst you have ever been, where do you think
you have been over the last week?”); and (5) “Arthritis
impact measurement scales” (AIMS; “Considering all the
ways your arthritis affects you….”). All PGA-VAS ver-
sions correlated strongly with each other (rho = 0.67–
0.87, p < 0.0001) [11]. However, when the phrasing of
PGA varied there was a difference in DAS28 scores, the
largest being 0.63 points. Such differences in score,
though small, could have clinical implications, i.e., on
the eligibility for biologic disease-modifying anti-
rheumatic drugs in countries where access to these
drugs is restricted based on strict DAS28 cutoffs.
However, although there are differences at the individual
level according to the concepts, wordings/phrasing used,
and time period assessed, these differences do not always
reflect differences at the group level [11, 12]. Direct com-
parison between studies is limited due to differences in
techniques used to assess the PGA and the population
used. Although this has not been explored, it is possible
PGA interpretation may be different in clinical trials
versus in “clinical practice”, in particular given population
selection and the often multiple use of PROs in studies.
Table 4 summarizes the main aspects of the PGA and
key messages presented in this review.
Interpretation of PGA levels for remission
Both DAS28-based remission and ACR/EULAR defined re-
mission criteria incorporate PGA into their scores [2, 35].
ACR/EULAR Boolean-based remission is defined as PGA
≤1 using a 0–10 VAS. Therefore, PGA plays a major role in
determining fulfillment of remission criteria in RA [6, 7, 35,
36]. In fact, PGA appears to be often a limiting factor for
remission—i.e., in patients with no visible inflammation, re-
mission may not be reached because of PGA. In a study
based on the DREAM remission induction cohort, ACR/
EULAR remission was present in 20.1 % of the patients. In
108 out of 512 patients, the PGA score was >1 using a 0–
10 VAS despite fulfillment of the remaining criteria (TJC28,
SJC28, and C-reactive protein in mg/dl ≤1). The specific
wording of questions and anchors used for the PGA were:
“Considering all of the ways your arthritis affects you, mark
“X” on the scale for how well you are doing” (“very well” to
“very poor”)” [37]. Similarly, close to half the patients
without visible inflammation in the ESPOIR cohort
did not achieve ACR/EULAR remission because of
PGA levels above 1/10 cm [38]. Thus, near-remission
defined as three of the four criteria (PGA excluded)
Table 3 Sensitivity of PGA to change in disease activity and comparison with other measures of disease
Study
group
Study details Main findings
Kaneko et
al. 2014
[46]
Prospective study
Newly diagnosed RA
75 patients
Discordance between PGA and EGA
PGA more sensitive for indicating progressive joint destruction and
functional impairment when compared with EGA
Discrepancy directed toward a worse assessment by patients
Pope et al.
2009 [52]
Prospective study of a large clinical practice
225 RA patients
MID estimates for: (1) HAQ-DI improvement and worsening
using PGA anchor; and (2) pain using a patient-reported pain
anchor.
MID scores for HAQ-DI in clinical practice were smaller than those seen
in clinical trials
MID scores were influenced by baseline HRQOL scores and may be
influenced by disease duration
MID changes were different for worsening (usually needing a larger
value) than for improving
MID for deterioration was much less than for improvement in patients
with more pain and impairment in physical function
Wells et al.
2008 [31]
Randomized controlled trial comparing abatacept (n = 258)
with placebo (n = 133) in anti-TNF poor respondents (ATTAIN
study)
Evaluation of the responsiveness of PROs in RA patients
PGA had larger relative percentage improvement with treatment (24 %)
than the generic quality of life outcomes SF-36 domains and compo-
nent scores (range 8–21 %)
PGA was more efficient than TJC in detecting a treatment effect
PGA was found to be in close proximity to the ESR, physician global
assessment and the PROs pain assessment, HAQ, bodily pain and
physical component score in terms of the standardized response means
Lassere et
al. 2001
[53]
Literature review on reliability for different classes of RA
measures
The SDD for the PGA (as well as for SJC, TJC, and pain) was found to be
large and it had poor reliability compared to multi-item measures of
physical and psychological function and radiologic measures
Ward 1994
[54]
Prospective study
24 RA patients
Determination of the relative accuracy and sensitivity to
change of 14 measures commonly used to assess arthritis
activity
High correlation between EGA, PGA, and pain scores
The PGA along with other measures of disease severity have been
shown to be more sensitive to change than laboratory measures (ESR)
EGA estimator global assessment, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, HRQOL Health Related Quality of
Life, MID minimally important difference, PGA patient global assessment, SDD smallest detectable difference, SF-36 36-item Short Form Health Survey, SJC swollen
joint count, TJC tender joint count, TNF tumor necrosis factor
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is the most frequent status [36–39]. Many of these
patients have a PGA above 1 but still quite low (usual
values are around 2/10) [40], perhaps suggesting a
need for revising the remission cutoff value for PGA.
Another question relates to the phrasing of PGA in
the remission criteria: would using the “disease activ-
ity” formulation make more sense than using the
“global health” formulation? Unpublished results
based on the ESPOIR French early arthritis cohort in-
dicate that the disease activity wording will lead to
less states of near-remission.
Overall, the high frequency of near-remission raises
the question of whether the way remission is defined
needs to be better clarified, i.e., should it reflect absence
of inflammation alone or absence of inflammation and
symptoms? The current amalgamation of joint counts
and C-reactive protein with PGA indeed leads to some
difficulties of interpretation, particularly in cases of near-
remission. Furthermore, the predictive validity of near-
remission is of clear importance, predicting long-term
outcomes of these patients. Our unpublished results in-
dicate near-remission predicts radiographic progression
over 3 years in early RA, as well as ACR/EULAR remis-
sion, in the ESPOIR cohort, suggesting near-remission is
a possible valid and even sufficient predictive outcome
in early RA [40, 41]. In the context of treating to target,
more work is needed on how to best interpret levels of
PGA when aiming for remission.
What are the elements explaining PGA?
PGA is a wide-reaching measure which may mean differ-
ent things for different people. Data are available on the
main drivers of PGA at the group level. PGA reflects
both disease activity and other factors. Given PGA is
assessed to provide information additional to joint
counts or acute phase reactants, it is expected there
might be some but not complete overlap.
PGA is explained by RA disease activity
Disease activity (i.e., RA inflammatory status) explains a
large part of PGA. Pain is a major cause of distress in
patients with RA and this, along with joint damage, is
among the important aspects/domains of RA that affect
patients’ lives and will contribute to how the PGA is
scored. Most studies indeed support that pain and func-
tional incapacity (evaluated by HAQ), are the most im-
portant drivers of PGA, and these outcomes are
indirectly reflecting RA disease activity. Furthermore, fa-
tigue plays a role and has also been found to be an im-
portant determinant of PGA [13]. However, joint counts
and acute phase reactants are not strong drivers of PGA
[12, 36]. In several studies pain is the single main driver
of PGA and may explain up to 75 % of the PGA result,
whether the concept is global health or disease activity
[11, 13]. This high contribution from pain is multifactor-
ial but strongly related to the inflammatory status [42].
This probably contributes to its high responsiveness in
trials. We should recognize, however, that pain itself is
multifactorial.
With regard to concepts underlying PGA, as expected
the disease activity-PGA is more related to inflammation
than the global health-PGA. Data from the Quantitative
Standard Monitoring of Patients with RA (QUEST-RA)
study support that the PGA is explained by different
drivers depending on the wording used [12].
Table 4 Summary of PGA aspects discussed in this review
Aspects covered Main findings
Description and practical
application
Two different concepts covered:
global health versus disease activity
The wording/phrasing and time-
reference used remain unstandardized,
leading to differences in interpretation
and therefore the responses obtained
There exist different scales to score
PGA
Psychometric properties Practical, feasible, and non-costly to
use in routine clinical practice
High face validity but its broad
concept can lead to difficulties with
interpretation
Good reliability and sensitive to
change, making it useful in clinical
practice and in research
Consequences of heterogeneity Differences in interpretation of results
Impact on DAS28 scoring and
therefore the achievement of
remission
Elements explaining PGA RA disease activity as indirectly
reflected by inflammation, pain, and
functional incapacity (partly due to
joint damage) and fatigue explain a
large component of the PGA
Psychological distress can result in
higher PGA
Conflicting evidence exists on the
impact of comorbidities on PGA
Non-RA factors impacting on PGA
include demographic characteristics,
education, culture, and geographic
origin
Differences in patient understanding
and interpretation affect the
responses
Discordance between PGA and
physician global assessment
More objective measures of disease, e.g.,
joint counts and acute phase reactants
lead to a higher physician global
assessment whereas pain and altered
quality of life without visible signs of
inflammation result in higher PGA
Patient–physician discordance can
affect DAS28 scoring and decision-
making, e.g., treatment escalation
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PGA is explained by non-RA factors
Over and above disease activity, PGA is affected by other
factors, including RA-related factors such as structural
damage and non-RA factors such as demographic
characteristics, education level, and perhaps culture and
geographic origin (Table 1) [36, 43]. Furthermore, inter-
pretation of the question by the patient may depend on
duration of disease through a “response shift” resulting
from better familiarity with symptoms and changes in
patient expectations, as mentioned above.
In the QUEST-RA study, psychological distress was an
important driver of PGA and was influenced by the differ-
ent wording used for the PGA: it was driving more im-
portantly global health than the disease activity wording
[13]. There is conflicting evidence on the impact of co-
morbidities on PGA: a cross-sectional study of US
Hispanics with RA showed no association between co-
morbidities, including depression and fibromyalgia, and
PGA [44]. In contrast, based on a study of 50 female pa-
tients with RA, in those with co-existing fibromyalgia, sig-
nificantly higher subjective items, including the PGA
(using global health wording) were noted [45]. Differences
in the study population and design, as well as the collec-
tion and recording of comorbidity data, could account for
the variations seen between studies.
Discordance between PGA and physician global
assessment
It is interesting to compare PGA to another global, “ge-
stalt” assessment of disease, which is the physician global
assessment. Physician global assessment is a well-validated
outcome which is recognized as part of the RA core set
[3]. Evidence suggests that discordance exists between pa-
tient and physician assessment of RA disease activity, with
studies consistently showing that PGA is very often scored
higher than physician global assessment [13, 43, 46–49].
Discordance in most studies is defined as a difference of
≥3/10 points between the PGA and physician global as-
sessment [12]. The prevalence of discordance using this
definition was found to be around 43 % in a recent meta-
analysis, indicating a different understanding or perspec-
tive of the same general concept [48].
What studies have shown to date is that variables that
are important to patients are not the same as those val-
ued by physicians as reflecting disease activity (Table 5).
Generally, more objective measures of disease, e.g., joint
counts and elevated acute phase reactants, lead to a
higher physician global assessment whereas pain and al-
tered quality of life without visible signs of inflammation,
but also comorbidities and psychological distress, will
lead to higher PGA (Table 5) [50]. In such cases of dis-
cordance, it is important to discuss the patient’s psycho-
logical status as well as personal life factors since the
solutions will not always lie in immunosuppressive drugs
but rather might depend on non-pharmacological inter-
ventions. This discordance may act as a clue to the pres-
ence of non-disease severity factors influencing the PGA.
Discussion
The increasing emphasis on the patients’ perspective of
health in considering priorities and making treatment
choices has resulted in PROs being a core part of routine
assessment of disease in RA and also an end-point in
clinical trials and observational studies. Recent guide-
lines are characterized by a shift from the traditional
approach of physician-led physical examination and in-
vestigations such as laboratory tests and radiographs
(the “biomedical model”) to a more patient-centered ap-
proach to care [51]. PGA is one of the most commonly
captured and reported PROs, mainly due to its simplicity
and its feasibility in both clinical practice and registers
as well as in clinical trial settings. It is strongly corre-
lated with other self-reported outcomes and carries im-
portant patient information. Therefore, despite the
controversy regarding the value of PROs including the
PGA, these represent the only way to assess some of the
aspects related to RA, for example, symptoms, justifying
that clinician-reported outcomes and PROs should be
considered as complementary to each other [52].
The lack of homogeneity in the concepts, wordings/
phrasings, and time period assessed by PGA threatens the
validity of PGA since it may lead to modified responses
resulting from the diversity of formulations [15]. Such
diversity can influence clinical and treatment decision-
making, highlighting the importance of standardizing
(where appropriate) and validating the question phrasing
as part of capturing information on PGA. We suggest that
emphasis is placed on reducing heterogeneity in wording/
phrasing and time period of the PGA in order to enable
more uniform capture (and hence interpretation) of infor-
mation across clinical and research settings.
The discordance between PGA and physician global
assessment demonstrated in many studies to date sug-
gests that perceptions of disease activity by patients may
be influenced by different factors, resulting in different
aspects of disease being measured. Such discordance can
negatively influence medical care, adherence to treat-
ment, and disease outcomes. Despite this, the use of
PROs such as PGA is particularly informative, bring-
ing additional information and perspective, especially
given the observed discordance of assessment be-
tween physicians and patients [52]. Like other PROs,
it is of particular value when changes in clinical
measurements or laboratory or radiographic out-
comes may not translate into meaningful benefits for
patients. In particular, the ease of use and feasibility
of PGA, with little or no training of patients re-
quired to complete it, means that it can be easily
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incorporated into busy clinical settings. However, it
is important that this contribution of patients to dis-
ease activity scores via the PGA is evaluated in a
standardized way.
We feel the lack of a standardized definition on the con-
cept, wording/phrasing, and time period assessed as part
of PGA represents one of its weaknesses. This does not
preclude the possibility of having more than one version
of PGA; however, it requires clarity with regard to what
version is selected and for which purpose (e.g., PGA for
disease activity or PGA for global health). We advocate
the use of a homogeneous wording in a specific context,
e.g., for repeated measures it is important to use the same
wording/phrasing. This is particularly important in rou-
tine clinical practice since it may lead to incorrect inter-
pretations regarding, for example, response to treatment.
Table 5 Discordance between PGA and estimator global assessment and associated factors
Study
group
Study description Patient
number (n)
Discordance between
PGA and EGA
Factors associated with discordance
Desthieux
et al. 2016
[55]
Systematic literature review and meta-
analysis
11,879
(12 studies)
Frequency of
discordance >2.7 cm
(weighted mean cutoff):
44.9 %
PGA > EGA: 79.1 %
PGA < EGA: 20.9 %
Drivers of global assessment:
PGA: pain (the most frequent driver of PGA, significant
in eight studies [100 % of studies analyzing this driver
of PGA]), functional incapacity, fatigue
EGA: swollen and tender joint counts, acute phase
reactants
Drivers of discordance:
Depressive symptoms, health literacy
Davis et al.
2014 [56]
Consecutive RA patients 127 Frequency of
discordance:
PGA > EGA: 16.5 %
PGA < EGA: 10.2 %
PGA > EGA: pain, fatigue, HAQ disability, poor health
related quality of life on the SF-36
PGA < EGA: higher numbers of swollen joints, positive
rheumatoid factor and lower pain; better overall
physical and mental health
Khan et al.
2012 [13]
Patients from the multi-national Quanti-
tative Standard Monitoring of Patients
with RA (QUEST-RA) database
7028 Mean PGA 4.0 ± 2.7 cm;
EGA 2.9 ± 2.4 cm
Frequency of
discordance >2 cm:
PGA > EGA: 30 %
PGA < EGA: 6.6 %
PGA > EGA: higher age; higher scores of pain, fatigue,
HAQ, and morning stiffness
PGA < EGA: higher SJC, TJC, ESR; lower fatigue score
Barton et al.
2010 [48]
Multi-site observational cohort with RA
adults consecutively enrolled from two
outpatient clinics in the US
223 Mean PGA 4.3 ± 2.6 cm;
EGA 3.1 ± 2.1 cm
Frequency of
discordance >2.5 cm:
PGA > EGA: 31 %
PGA < EGA: 5 %
PGA > EGA: higher HAQ score; lower SJC; greater
depressive symptoms
Nicolau G
et al. 2004
[43]
Single center cohort of RA patients in
Brazil
80 Frequency of
discordance ≥1 cm:
PGA > EGA: 44 %
PGA < EGA: 28 %
Frequency of
discordance ≥3 cm
PGA > EGA: 24 %
PGA < EGA: 9 %
PGA > EGA: higher pain and HAQ scores and tendency
for higher number of comorbid conditions
Studenic
et al. [42]
Single center observational cohort of
RA patients initiating MTX in Austria
646 Mean PGA 3.9 ± 2.7 cm;
EGA 2.3 ± 2.1 cm
Frequency of
discordance ≥0.5 cm:
PGA > EGA: 61 %
PGA < EGA: 15 %
PGA > EGA: higher pain and lower SJC
EGA estimator global assessment, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Damage Index, MID minimally important differ-
ence, PGA patient global assessment, SDD smallest detectable difference, TJC tender joint count, SF-36 36-item Short Form Health Survey
Table 6 Proposals of wording/phrasing in view of homogenizing PGA
Concept Global health Disease activity
Wording/phrasing “Considering all the ways in which illness
and health conditions may affect you at this
time, please make a mark below to show
how you are doing”
“Considering all the ways your arthritis
has affected you, how do you feel your
arthritis is today?”
Scoring 0–100 VAS or 0–10 NRS 0–100 VAS or 0–10 NRS
Anchors Very well–very poorly Inactive–very active
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In terms of practical recommendations, the suggestion of
the authors is that phrasing of PGA may at this stage be
proposed as capturing (1) either global health or disease ac-
tivity which is (2) related to arthritis and captured by the
reference period of (3) today/this point in time. Examples
would be the formulation proposed in the RAPID 3 score
for global health or the one proposed in the EULAR/ACR
remission criteria for disease activity (Table 6) [37].
The choice between the two concepts will depend on
the objective of the measurement of the PGA. The glo-
bal health question gives more holistic information on
patient status since it includes to a wider extent ele-
ments such as comorbidities and psychological distress.
The disease activity-PGA is more in line with more ob-
jective measures of disease and assesses more closely the
inflammatory burden.
Conclusions
PGA is a key outcome measure in RA with clear validity
and usefulness. However, the lack of a “gold standard” in
terms of its wording/phrasing and time period assessed
necessitates more research into this field in order to
avoid pitfalls in interpretation and, consequently, in the
achievement of treatment targets. In this review, we
propose homogenized wordings which may be consid-
ered for future studies. Importantly, a clear understand-
ing of what PGA measures and potential sources of
variation in its reporting is key to accurate interpret-
ation. Furthermore, this review gives insights into factors
associated with and affecting PGA—for example, its
close association with pain, mood, and fatigue and issues
around discordance with physician global assessment.
This may be informative in guiding interventions to im-
prove care and overall quality of life for RA patients.
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